Where is SOLY (+37% from our initial alert) headed next?

Soliton (SOLY) rallied 37% in the weeks after Mike Paulenoff highlighted it for MPTrader members on March 10.  Where's it headed next?
SOLY is a medical device/biotech company developing a promising product, with a 2-year chart setup that caught Mike's attention early in the year, suggesting sooner than later that price would reflect the underlying company fundamentals.
Early on March 10, with the stock at 13.65, Mike wrote: "SOLY continues to exhibit an extremely promising and potentially explosive intermediate-term set up. Let's notice that into last week's weakness, SOLY spiked down right to its up-sloping 50 DMA (now 11.22), which contained the price pressure, and served as the launch pad for a sharp recovery into a near 2-year resistance zone from 14.00 to 15.50. If SOLY either chews its way through the resistance, or is the beneficiary of a forthcoming bullish catalyst, it has potential for a vertical assault to 20-21 and then to 25-26. At this juncture, anyone long SOLY should use the 50 DMA as a stop level."
Mike continued to monitor SOLY closely thereafter, and noting last (on March 15) that the stock had taken out 10 months of resistance at 13.80-15.50, and looked higher.
The following day, SOLY popped to 18.63.
Where's it headed next?  SOLY closed at 17.38 on Friday, atop its two year resistance zone, which now serves as support.
Join Mike and our MPTrader members for their laser-focused discussions about promising technical and fundamental set ups in stocks, ETFs, macro indices, cryptocurrencies, and precious metals.

More Top Calls From Mike

  • Action-Oriented Trade Set-Ups in Stocks & ETFs
  • Macro Analysis of the Broader Markets
  • Detailed Technical Guidance for each Trading Idea
  • Live Interaction w/ Mike & Our Member Community
  • And Much, Much More!
Join Now! - Special Offer!
Veteran Wall Street analyst and financial author, Mike provides detailed and timely analysis and trade set-ups on a range of markets. Read more...

Have Mike's “Out Front” morning analysis delivered FREE to your email inbox twice weekly!